• 1
    Davis J, Shock N. The effect of theophylline ethylene diamine on renal function in control subjects and in patients with congestive heart failure. J Clin Invest 1949; 28: 14591468.
  • 2
    Sigurd B, Olesen K. The supra-additive natriuretic effect addition of theophylline ethylenediamine and bumetanide in congestive heart failure. Am Heart J 1977; 94: 168174.
  • 3
    Lochan S, Adeniyi-Jones S, Assadi F, Frey B, Marcus S, Baumgart S. Coadministration of theophylline enhances diuretic response to furosemide in infants during extracorporeal membrane oxygenation. A randomized controlled pilot study. J Pediatr 1998; 133: 8689.
  • 4
    Pretzlaff R, Vardis R, Pollack M. Aminophylline in the treatment of fluid overload. Crit Care Med 1999; 27: 27822785.
  • 5
    Nassif E, Weinberger M, Shannon D, Guiang S, Hendeles L, Jimenez D et al. Theophylline disposition in infancy. J Pediatrics 1981; 98: 158161.
  • 6
    Moore E, Faix R, Banagale R, Grasela T. The population pharmacokinetics of theophylline in neonates and young infants. J Pharmacokinetics Biopharmaceutics 1989; 17: 4766.
  • 7
    Loughnan P, Sitar D, Ogilvie R, Eisen A, Fox Z, Neims A. Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. J Pediatr 1976; 88: 874879.
  • 8
    Lee T, Charles B, Steer P, Flenady V, Grant T. Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. Br J Clin Pharmacol 1996; 41: 191200.
  • 9
    Gilman J, Gal P, Levine R, Hersh C, Vildan Erkan N. Factors influencing theophylline disposition in 179 newborns. Therapeutic Drug Monitoring 1986; 8: 410.
  • 10
    Elliott E, Koysooko R, Levy G. Pharmacokinetics of theophylline in children with asthma. Pediatrics 1976; 58: 542547.
  • 11
    Du Preez M, Botha J, McFayden M, Holford N. The pharmacokinetics of theophylline in premature neonates during the first few days after birth. Therapeutic Drug Monitoring 1999; 21: 598603.
  • 12
    Driscoll M, Ludden T, Casto D, Littlefield L. Evaluation of theophylline pharmacokinetics in a pediatric population using mixed effects models. J Pharmacokinetics Biopharmaceutics 1989; 17: 141168.
  • 13
    Aranda J, Sitar D, Parsons W, Loughnan P, Neims A. Pharmacokinetic aspects of theophylline in premature newborns. N Engl J Med 1976; 295: 413416.
  • 14
    Karlsson M, Thomson A, McGovern E, Chow P, Evans T, Kelman A. Population pharmacokinetics of rectal theophylline in neonates. Therapeutic Drug Monitoring 1991; 13: 195200.
  • 15
    Rosen J, Danish M, Ragni M, Lopez Saccar C, Yaffe S, Lecks H. Theophylline pharmacokinetics in the young infant. Pediatrics 1979; 64 (2): 248251.
  • 16
    Peek G, Killer H, Sosnowski A, Firmin R. Extracorporeal membrane oxygenation: potential for adults and children? Hospital Med (London) 1998; 59: 304308.
  • 17
    Bartlett R, Roloff D, Custer J, Younger J, Hirschl R. Extracorporeal life support. The University of Michigan Experience. J Am Med Assoc 2000; 283: 904908.
  • 18
    Mulla H, Lawson G, Firmin R, Upton D. Drug disposition during extracorporeal membrane oxygenation (ECMO). Paediatric Perinatal Drug Ther 2001; 4: 109120.
  • 19
    Mulla H, Lawson G, Von Anrep C, Burke M, Upton D, Firmin R et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion 2000; 15: 2126.
  • 20
    Cohen P, Collart L, Prober C, Fischer A, Blaschke T. Gentamicin pharmacokinetics in neonates undergoing extracorporeal membrane oxygenation. Paediatric Infect Dis 1990; 9: 562566.
  • 21
    Sheiner L, Rosenberg B, Arathe V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinetics Biopharmaceutics 1977; 5: 445479.
  • 22
    Sheiner L, Grasela T. An introduction to mixed effect modelling. concepts, definitions, and justification. J Pharmacokinetics Biopharmaceutics 1991; 19 (June Suppl.): 11S24S.
  • 23
    Pharsight. Winnonmix Professional, 2.0.1 edn. Mountain View, CA: Pharsight Corp., 19932000.
  • 24
    Compaq. Compaq Visual Fortran Professional Edition, 6.5 edn. Houston, Compaq Computer Corp., 2000.
  • 25
    Sun H, Fadiran E, Jones C, Lesko L, Huang S-M, Higgins K et al. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinetics 1999; 37: 4158.
  • 26
    Fiset P, Mathers L, Engstrom R, Fitzgerald D, Brand S, Hsu F et al. Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. Anesthesiology 1995; 83: 944955.
  • 27
    Zomorodi K, Donner A, Somma J, Barr J, Sladen R, Ramsay J et al. Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. Anesthesiology 1998; 89: 14181429.
  • 28
    Kerbusch T, Kraker JD, Mathot R, Beijnen J. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach. Clin Pharmacokinetics 2001; 40: 615625.
  • 29
    Sheiner L, Beal S. Some suggestions for measuring predictive performance. J Pharmacokinetics Biopharmaceutics 1981; 9: 503512.
  • 30
    Brazier J, Renaud H, Ribon B, Salle B. Serum xanthine levels in low birthweight infants treated or not treated with theophylline. Arch Dis Childhood 1979; 54: 194199.
  • 31
    Jones R, Baillie E. Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. Arch Dis Childhood 1979; 54: 190193.
  • 32
    Hilligross D, Jusko W, Koup J, Giacoia G. Factors affecting theophylline pharmacokinetics in premature infants with apnoea. Dev Pharmacol Therapeutics 1980; 1: 615.
  • 33
    Estelle F, Simons R, Rigatto H, Simons K. Pharmacokinetics of theophylline in neonates. Semin Perinatol 1981; 5: 337345.
  • 34
    Gal P, Boer H, Toback J, Wells T, Erkan N. Effect of asphyxia on theophylline clearance in newborns. Southern Med J 1982; 75: 836838.
  • 35
    MacGillivray T, Jennings R, Rudolph A, Ring E, Adzick N, Harrison M. Vascular changes with in utero correction of diaphragmatic hernia. J Pedia Surg 1994; 29: 992996.
  • 36
    Mckindley D, Hanes S, Boucher B. Hepatic drug metabolism in critical illness. Pharmacotherapy 1998; 18: 759778.
  • 37
    Jusko W, Gardner M, Mangione A, Schentag JJ, Koup JR, Vance JW. Factors affecting theophylline clearance: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharmaceut Sci 1979; 68: 13581366.
  • 38
    Self T, Chafin C, Soberman J. Effect of disease states on theophylline serum concentrations: are we still vigilant? Am J Med Sci 2000; 319: 177182.
  • 39
    ECMO: Extracorporeal Cardiopulmonary Support in Critical Care, 2nd edn, eds ZwischenbergerJB, SteinhornRH, BartlettRH. Ann Arbor, MI: Extracorporeal Life Support Organization, 2000.
  • 40
    Shevde K, Dubois W. Pro: pulsatile flow is preferable to nonpulsatile flow during cardiopulmonary bypass. J Cardiothoracic Anaesth 1987; 1: 165168.
  • 41
    Rowland M, Tozer T. In Clinical Pharmacokinetics: Concepts and Applications, 3rd edn, eds FortarJO, ArneilGC. Philadelphia: Lippincott Williams & Wilkins, 1995.
  • 42
    Textbook of Paediatrics, 3rd edn. Edinburgh: Churchill Livingstone, 1984.